These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31674239)

  • 1. Prescribing and adherence to bone protection medications following hip fracture in the United Kingdom: results from the World Hip Trauma Evaluation (WHiTE) cohort study.
    Cehic M; Lerner RG; Achten J; Griffin XL; Prieto-Alhambra D; Costa ML
    Bone Joint J; 2019 Nov; 101-B(11):1402-1407. PubMed ID: 31674239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients' first-year adherence to different anti-osteoporotic therapy after hip fractures.
    Kim SJ; Cho YJ; Lee DW
    Injury; 2021 Jun; 52(6):1506-1510. PubMed ID: 33223260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do patients receive recommended treatment of osteoporosis following hip fracture in primary care?
    Petrella RJ; Jones TJ
    BMC Fam Pract; 2006 May; 7():31. PubMed ID: 16684358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis.
    Desai RJ; Mahesri M; Abdia Y; Barberio J; Tong A; Zhang D; Mavros P; Kim SC; Franklin JM
    JAMA Netw Open; 2018 Jul; 1(3):e180826. PubMed ID: 30646034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture.
    Jennings LA; Auerbach AD; Maselli J; Pekow PS; Lindenauer PK; Lee SJ
    J Am Geriatr Soc; 2010 Apr; 58(4):650-7. PubMed ID: 20398147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit.
    Gamboa A; Duaso E; Marimón P; Sandiumenge M; Escalante E; Lumbreras C; Tarrida A
    Osteoporos Int; 2018 Oct; 29(10):2309-2314. PubMed ID: 30076454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study.
    Clemens KK; Jeyakumar N; Ouédraogo AM; Thain J; Khan T
    Arch Osteoporos; 2020 Aug; 15(1):133. PubMed ID: 32816151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
    Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real-world study of treatment patterns among patients with osteoporotic fracture: analysis of a Japanese hospital database.
    Hagino H; Yoshinaga Y; Hamaya E; Lin TC; Ajmera M; Meyers J
    Arch Osteoporos; 2023 Jan; 18(1):23. PubMed ID: 36683098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment.
    Yeh WL; Su CY; Chang CW; Chen CH; Fu TS; Chen LH; Lin TY
    BMC Musculoskelet Disord; 2017 Dec; 18(1):527. PubMed ID: 29237448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients.
    Tsai YL; Wu CH; Li CC; Shih CA; Chang YF; Hwang JS; Tai TW
    Osteoporos Int; 2023 Oct; 34(10):1783-1791. PubMed ID: 37466659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
    Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
    Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
    Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
    Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
    Lyu H; Zhao SS; Yoshida K; Tedeschi SK; Xu C; Nigwekar SU; Leder BZ; Solomon DH
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5611-5620. PubMed ID: 31265071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current approaches to secondary prevention after hip fracture in England and Wales - an analysis of trends between 2016 and 2020 using the National Hip Fracture Database (NHFD).
    Mohsin Z; Javaid MK; Johansen A
    Arch Osteoporos; 2023 Jul; 18(1):93. PubMed ID: 37428295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Undertreatment of osteoporosis following hip fracture: a retrospective, observational study in Singapore.
    Chau YT; Nashi N; Law LS; Goh RKH; Choo SX; Seetharaman SK
    Arch Osteoporos; 2020 Sep; 15(1):141. PubMed ID: 32918196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in osteoporosis treatment initiation in geriatric patients admitted under the hip-fracture pathway.
    Wen AFYH; Chong BYK; Joseph LV; Bee JKS; Sen HT; Mamun K
    Arch Osteoporos; 2022 Oct; 17(1):136. PubMed ID: 36271963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fracture prevention service to bridge the osteoporosis care gap.
    Ruggiero C; Zampi E; Rinonapoli G; Baroni M; Serra R; Zengarini E; Baglioni G; Duranti G; Ercolani S; Conti F; Caraffa A; Mecocci P; Brandi ML
    Clin Interv Aging; 2015; 10():1035-42. PubMed ID: 26150707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teriparatide Improves Fracture Healing and Early Functional Recovery in Treatment of Osteoporotic Intertrochanteric Fractures.
    Huang TW; Chuang PY; Lin SJ; Lee CY; Huang KC; Shih HN; Lee MS; Hsu RW; Shen WJ
    Medicine (Baltimore); 2016 May; 95(19):e3626. PubMed ID: 27175673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Following hip fracture, hospital organizational factors associated with prescription of anti-osteoporosis medication on discharge, to address imminent refracture risk: a record-linkage study.
    Patel R; Judge A; Johansen A; Javaid MK; Griffin XL; Chesser T; Griffin J; Marques EMR; ; Ben-Shlomo Y; Gregson CL
    J Bone Miner Res; 2024 Aug; 39(8):1071-1082. PubMed ID: 38988134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.